Introduction: Genome-wide association studies (GWAS) have consistently identified specific lung cancer susceptibility regions. We evaluated the lung cancer-predictive performance of single-nucleotide polymorphisms (SNPs) in these regions. Methods: Lung cancer cases (N = 778) and controls (N = 1166) were genotyped for 77 SNPs located in GWAS-identified lung cancer susceptibility regions. Variable selection and model development used stepwise logistic regression and decision-tree analyses. In a subset nested in the Pittsburgh Lung Screening Study, change in area under the receiver operator characteristic curve and net reclassification improvement were used to compare predictions made by risk factor models with and without genetic variables. Results: Variable selection and model development kept two SNPs in each of three GWAS regions, rs2736100 and rs7727912 in 5p15.33, rs805297 and rs1802127 in 6p21.33, and rs8034191 and rs12440014 in 15q25.1. The ratio of cases to controls was three times higher among subjects with a high-risk genotype in every one as opposed to none of the three GWAS regions (odds ratio, 3.14; 95% confidence interval, 2.02-4.88; adjusted for sex, age, and pack-years). Adding a three-level classified count of GWAS regions with high-risk genotypes to an age and smoking risk factor-only model improved lung cancer prediction by a small amount: area under the receiver operator characteristic curve, 0.725 versus 0.717 (p = 0.056); overall net reclassification improvement was 0.052 across low-, intermediate-, and high-6-year lung cancer risk categories (<3.0%, 3.0%-4.9%, ≥5.0%). Conclusion: Specifying genotypes for SNPs in three GWASidentified susceptibility regions improved lung cancer prediction, but probably by an extent too small to affect disease control practice.
T ypically using many hundreds of thousands of singlenucleotide polymorphisms (SNPs) and working to identify regions of the human genome that associate with a particular trait or disease, genome-wide association studies (GWAS) compare the frequency of common inherited variation between two groups of individuals. Comparing individuals with and without lung cancer, this approach has reproducibly identified several susceptibility regions of interest. [1] [2] [3] [4] [5] Although these genomic regions contain multiple potentially relevant genes, we currently lack a firm biological understanding of the causal molecular processes that link them to lung cancer. 6 The regions implicated in GWAS of lung cancer may act indirectly by affecting intensity of cigarette smoking or personal susceptibility to chronic obstructive pulmonary disease (COPD), 7 two potent lung cancer risk factors. 8 The identification of susceptibility loci has stimulated interest in the use of genetic information to help identify persons at particularly high risk of developing lung cancer. 9 Genetic information might be used to improve the prediction accuracy of currently available models based on cigarette smoking and age. [10] [11] [12] [13] [14] [15] Selecting persons according to predictions made by more accurate models may help improve the efficiency and safety of lung cancer screening with low-dose computed tomography (CT), 16 a public health-relevant issue in light of the recent Centers for Medicare and Medicaid Services funding decision adding lung cancer screening to Medicare. 17 With these thoughts in mind, we aimed to evaluate the predictive performance of common SNPs located in regions previously identified in GWAS of lung cancer or COPD. [1] [2] [3] [4] [5] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 
MATERIALS AND METHODS

Study Subjects
Consented subjects originated from two studies approved by the University of Pittsburgh Institutional Review Board. A clinical study contributed 45-to 85-year-old 10 or more pack-year current or former cigarette smokers who received diagnostic, staging, or therapeutic surgery after 2001 at the University of Pittsburgh Medical Center for noncarcinoid lung cancer and who provided a research blood sample within 1 year of diagnosis. The second group of subjects came from the Pittsburgh Lung Screening Study (PLuSS), a Pittsburghbased CT lung cancer screening study that enrolled, between 2002 and 2005, 50-to 79-year-old current or former cigarette This second study group included a set of lung cancer cases, and a lung cancer-free simple random sample, enriched with persons found to have one or more benign noncalcified nodules, 5 to 19 mm in diameter on first CT, or growing or new on follow-up CT. Our genotyping studies added persons with nodules to enhance parallel studies of circulating proteinbased biomarkers and early lung cancer detection.
These two sources identified 2292 individuals in all, including 2189 (95.5% of 2292) with DNA available for analysis and 2117 (96.7% of 2189) with a DNA sample that passed all genotype quality control checks, including SNP call rate 95% or greater. After 173 exclusions (five for missing sex, one for age <50 years, 10 for <10 pack-years, 14 for lung cancer not biopsy confirmed, and 143 for non-white race), 1944 subjects (91.8% of 2117) remained, 778 lung cancer cases (600 clinical and 178 PLuSS), and 1166 lung cancer-free controls (861 selected at random and 305 chosen intentionally for nodule presence). Active lung cancer surveillance after an initial CT screening extended a median 7.3 years (5th to 95th percentile 1.2 to 10.8 years) and a median 10.4 years (5th to 95th percentile 8.8 to 11.7 years) for control subjects who were dead and alive, respectively, at last contact. To reduce confounding related to population stratification, analyses excluded nonwhite race subjects and used ancestry-informative markers to verify white race.
For clinical cases, ancillary data (sex, age at diagnosis, cigarette pack-years, and spirometry results) were extracted from medical records. For PLuSS cases and controls, ancillary data collected through standardized self-administered questionnaire included smoking intensity (cigarettes per day), years of smoking, family history of lung cancer, respiratory symptoms (cough, phlegm, and wheeze), and medical history (doctor diagnosis of emphysema or bronchitis). As previously described, 29 additional baseline information available for the PLuSS cases and controls included severity of airflow limitation measured by spirometry and severity of emphysema seen on CT. 
SNP Selection and Genotyping
Statistical Analysis
Using a data set that replaced missing genotypes with values imputed from haplotype frequencies estimated by expectation maximization, 30 we used stepwise logistic regression (p entry < 0.25, p stay < 0.15), one GWAS region at a time, to select SNPs independently associated with lung cancer risk. Using weights to balance the numbers of cases and controls and working one GWAS region at a time, we used a WEKA 31 implementation of the C4.5 algorithm 32 to translate the independent SNP variables into decision trees. To evaluate the effects of genetic variables on lung cancer risk prediction, we restricted analyses to the lung cancer cases nested in PLuSS, along with the comparable controls selected at random. We used net reclassification improvement (NRI 33 ) to compare lung cancer predictions made by appropriately calibrated models with and without genetic variables. Base models estimated individual risks by means of logistic regression and a risk factor score that tallied points for the following four risk factors: duration of smoking, age, cigarettes per day, and smoking status (Supplemental Table  2 , Supplemental Digital Content, http://links.lww.com/JTO/ A889). To recalibrate a prediction model, we reweighted case and control observations as desired and then re-estimated the intercept term in logistic regression with the logit of case-control model predictions entered as an offset. Statistical analyses were completed in SAS 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Selected characteristics of the study population are presented in Table 2 . Women were similarly represented in the case and control groups. The cases were significantly older than the controls and had accrued more cigarette pack-years. The majority of the cases were diagnosed with non-small-cell lung cancer; adenocarcinoma and squamous-cell carcinoma were the most often observed histological types.
Stepwise logistic regression selected two, three, and two SNPs in 5p15.33 (rs2736100 and rs7727912), 6p21.33 (rs805297, rs2295663, and rs1802127), and 15q25.1 (rs8034191 and rs12440014), respectively ( Table 3 ). The 5p15.33 decision-tree analysis produced a lung cancer class that included both the carriers of the rs7727912 minor allele and the homozygotes for the rs2736100 common allele (Supplemental Figure 1A , Supplemental Digital Content, http://links.lww.com/JTO/A889). The 6p21.33 lung cancer class included both the carriers of the rs1802127 minor allele and the homozygotes for the rs805297 common allele (Supplemental Figure 1B , Supplemental Digital Content, http://links.lww.com/JTO/A889). Finally, the 15q25.1 lung cancer class included rs12440014 common allele homozygotes with one or two copies of the rs8034191 minor allele (Supplemental Figure 1C , Supplemental Digital Content, http://links.lww.com/JTO/A889). All subsequent results used these classification results from decision-tree analysis to distinguish high from low risk for lung cancer.
Control group characteristics according to decisiontree-determined risk at 5p15.33, 6p21.33, and 15q25.1 are presented in Supplemental Tables 3, 4 , and 5 (Supplemental Digital Content, http://links.lww.com/JTO/A889), respectively. High-risk controls had more emphysema on CT (p = 0.22, <0.01, and <0.01 for 5p15.33, 6p21.33, and 15q25.1, respectively). Twenty-one percent, 43%, and 36% of controls satisfied decision-tree definitions of high risk at zero, only one, and more than one GWAS region, respectively. Cigarettes per day, pack-years, prevalence of doctor-diagnosed emphysema or bronchitis, and emphysema severity increased along with the number of GWAS regions that satisfied decision-tree definitions of high risk (Table 4) . a Fifty-three subjects could not be classified because of missing genotype data. b Differences in characteristics between groups were assessed using chi-square tests. First-degree relative with lung cancer (data missing in two, four, and two controls with 0, 1, and >1 GWAS risk marker). GWAS, genome-wide association studies; symptoms, symptom (cough, phlegm, and wheeze) count; COPD, chronic obstructive pulmonary disease (doctor diagnosis of emphysema or bronchitis); GOLD, Global Initiative for Chronic Obstructive Lung Disease severity of airflow limitation.
We tabulated cases and controls, first according to a three GWAS region cross-classification of decision-treedetermined SNP configurations associated with high versus low lung cancer risk and then according to a three-level classified count of GWAS regions showing the high-risk SNP configuration (Table 5) . Table 5 shows, for example, a threefold higher ratio of cases to controls among subjects with a highrisk genotype in every one as opposed to none of the three GWAS regions (odds ratio, 3.14; 95% confidence interval, 2.02-4.88; adjusted for sex, age, and cigarette pack-years). Unadjusted and adjusted (sex, age, and pack-years) lung cancer risk increased (p < 0.001) in step with the number of GWAS regions that contained a SNP configuration associated with high lung cancer risk.
We subsequently used the prospective data from PLuSS to make externally valid inferences about the contributions from genetic variables to risk prediction. Associations between the GWAS variables and lung cancer were preserved, even after adjustments for a score that added points together for the four risk factors: duration of smoking, age, cigarettes per day, and smoking status (Table 5;  Supplemental Table 2 , Supplemental Digital Content, http:// links.lww.com/JTO/A889). Adding a three-level high-risk GWAS region count variable (0, 1, and ≥2 high-risk GWAS regions) to the risk factor score-only model increased area under the receiver operator characteristic curve by 0.008 units (0.717 to 0.725; p = 0.056). We recalibrated both the risk factor score-only model and the risk factor score plus GWAS region count variable model to four events per 100 (absolute 6-year lung cancer incidence observed in PLuSS; data not shown). Across low-(<3.0%), intermediate- Table 6 ).
DISCUSSION
Having genotyped 778 cases and 1166 controls for 77 SNPs located in regions identified by GWAS of lung cancer or COPD, our methods built on six SNPs, two from each of the following three regions, 5p15.33, 6p21.33, and 15q25.1. These three regions have withstood the test of time as the source of valid markers of susceptibility to lung cancer in white populations 7 and contain cancer-relevant genes that include telomerase reverse transcriptase (TERT; essential for telomerase production and maintenance of telomeres) and CLPTM1-like (CLPTM1L; reported to protect against apoptosis 34 ) in 5p15.33, BCL2-associated athanogene 6 (BAG6; required for p53-mediated response to DNA damage and stress) and mutS homolog 5 (MSH5; involved in DNA mismatch repair) Count of GWAS regions with SNP configurations associated with high lung cancer risk. GWAS, genome-wide association studies; SNP, single-nucleotide polymorphism; CI, confidence interval; PluSS, Pittsburgh Lung Screening Study; LO, decision-treedetermined SNP configuration associated with low lung cancer risk; HI, decision-tree-determined SNP configuration associated with high lung cancer risk; OR, odds ratio; OR a , odds ratio adjusted of sex, age (three groups), and pack-years (four groups); OR b , odds ratio adjusted for a risk factor score that tallied points for duration of smoking, age, cigarettes per day, and smoking status (Supplemental Table 2 , Supplemental Digital Content, http://links.lww.com/JTO/A889). in 6p21.33, and the nicotinic cholinergic receptor genes (CHRNA3, CHRNA4, CHRNA5; associated with nicotine addiction and smoking cessation) in 15q25.1. Using ancillary information provided by the lung cancer-free controls, our results shown in Table 4 support associations previously reported between GWAS-identified markers of lung cancer risk and other factors capable of mediating the lung cancer effects of these inherited genetic differences. Mediating factors relevant to our study included intensity of cigarette smoking, as measured by cigarettes per day, and COPD, as measured by self-reported doctor diagnosis, emphysema on CT, and airflow limitation on spirometry. Each GWAS region appeared to contribute independently to risk, a pattern discernable by comparing subjects with high-risk genotypes in only one as opposed to none of the three GWAS regions (odds ratio [95% confidence interval] for high GWAS risk at 5p15. 33 Table 5 ). Statistical control for case-control differences in age and smoking did not diminish these lung cancer associations with genetic risk (Table 5) .
By comparing extreme categories, a high-risk genotype in every one as opposed to none of the three GWAS regions, we explored the maximum extent to which GWAS SNP classifications may discriminate between persons with and without lung cancer risk. Six percent and 21% of 1113 controls had high-risk genotypes in three and zero GWAS regions, respectively, with the ratio of cases to controls significantly elevated threefold in the former as opposed to the latter category after adjustment for sex, age, and cigarette pack-years. However, to illustrate the potential usefulness of the lung cancer discrimination achievable with GWAS SNP classification in practice, we formed three prudent categories defined by presence of a high-risk genotype in none, only one, and more than one GWAS region. Adding this high-risk GWAS region count variable to an age and smoking risk factor-only model improved lung cancer prediction, as measured by an area under the receiver operator characteristic curve change of 0.008 and an NRI overall of 0.052 across low-, intermediate-, and high-risk categories. These risk categories spanned the average 6-year lung cancer risk observed in PLuSS, a representative cohort of current and former smokers. 28 To discuss these improvements in possibly more meaningful terms, we will use our theoretical cohort of 1000 persons ( 28 we evaluated SNPs in GWASidentified regions as predictors of lung cancer risk, an effort only possible with prospective data. Several previous studies have measured the improvements achieved by adding SNP genotype information to an otherwise conventional lung cancer prediction model. [35] [36] [37] [38] [39] However, none used prospective data to systematically evaluate SNPs from GWAS regions. Though unique in these regards, our study faced several limitations. First, the numbers of cases and controls available, particularly the number of cases nested in PLuSS, was relatively small, which limited the precision of some of our estimates of association between genetic risk and lung cancer (Table 5) . Second, having used statistical criteria to select six SNPs from a list of 74 candidates, we did not correct our estimates of prediction accuracy for model overfitting. Therefore, the improvements in prediction attributed to genetic variables are optimistic, potentially representing only an upper bound of the benefits that might be possible. Third, not all cases and controls came from a single well-defined source. To help select SNPs and build models, we supplemented the cases nested in PLuSS with cases seen in the clinic and added subjects with one or more benign nodules to the controls randomly selected from PLuSS. However, we did not observe statistically significant differences in a Predictions based on a risk factor score that tallied points for duration of smoking, age, cigarettes per day, and smoking status (Supplemental Table 2 , Supplemental Digital Content, http://links.lww.com/JTO/A889).
genotype frequencies between cases obtained from the clinic as opposed to PLuSS or between controls selected randomly as opposed to intentionally (data not shown). Fourth, we based estimates of NRI on notions about current and former smokers who may or may not be appropriate candidates for lung cancer screening with low-dose CT. No universally accepted risk threshold exists for separating smokers between these two groups. 9 However, when divided at the 0.03 risk threshold by the risk factor-only model used for NRI calculation (Table 6 ), controls randomly selected from PLuSS split between a lower (N = 450) and higher (N = 411) risk group, two thirds in the former failing and nearly all (93%) in the latter satisfying minimum age and pack-year requirements for lung cancer screening, as established by the U.S. Preventive Services Task Force. 40 Finally, our base models considered a limited set of risk factors related to sex, age, or smoking. Approaches that consider additional risk factors, such as COPD, may reduce even further the incremental improvements in prediction possible through genetic information.
In conclusion, in line with what has been reported for other cancer sites, 41, 42 adding genetic information from six SNPs located in genomic regions identified by GWAS to basic models that included critical risk factors related to age and smoking resulted in only small improvements in lung cancer risk prediction. Unfortunately, the improvements observed are likely too small to affect disease control practice.
